Tolperisone, a skeletal muscle relaxant, was first developed in the mid-20th century in Eastern Europe, and has been used throughout the globe since—except in the United States. Randall Kaye, MD, the chief medical officer of Neurana Pharmaceuticals, based in San Diego, talks about his company’s journey bringing the drug to the U.S. market, specifically on his research presented at PAINWeek 2020.
MARCH 16, 2021